Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma
Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is ...
Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is ...
CRISPR Therapeutics AG (NASDAQ:CRSP) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni ...
Cancers of the head and neck can be treated with several drugs on the market, but for certain patients diagnosed ...
Repare Therapeutics has three cancer drug candidates in the clinic and another one expected to enter Phase 1 by the ...
One challenge for developing drugs for autoimmune diseases is that biologic therapies can spark an immune response against them. Immunology ...
Immunology and inflammation biotech Alumis has demonstrated its lead drug candidate can hit a certain validated target to treat plaque ...
Exscientia founder and CEO Andrew Hopkins is out of a job after an investigation found the CEO engaged in relationships ...
Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of ...
Goldman Sachs Asset Management has expanded to biotech investments in recent years. The investment firm is now preparing to ramp ...
Copyright © 2024 EuroAsia24 News.
EuroAsia24 News is not responsible for the content of external sites.